Tuberculosis Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Tuberculosis Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Studies from University of London, Imperial College provide new data on HIV/AIDS
June 15th, 2009
According to recent research from London, the United Kingdom, "HIV-tuberculosis coinfection is complex partly because rifamycins reduce therapeutic levels of protease inhibitors and nonnucleoside reverse transcriptase inhibitors, leading to potential virological failure." "One therapeutic option is to use nucleos(t)ide-only regimens that have minimal interactions with antituberculous therapy. We report the largest published series of HIV-tuberculosis coinfected patients successfully treated with nucleos(t)ide regimens and antituberculous therapy," wrote D. Armstrongjames and colleagues, University of London, Imperial College. The researchers...
Source: Tuberculosis Week (2009-06-15)
|
